Unicycive Investors Have Until Nov. 2 to Seek Lead Plaintiff Role
Investors in Unicycive Therapeutics have until November 2, 2026, to seek appointment as lead plaintiff in a securities fraud class action, according to a law firm reminder.
Investors in Unicycive Therapeutics have until November 2, 2026, to seek appointment as lead plaintiff in a securities fraud class action, according to a law firm reminder.